DEVELOPMENTS OF RUSSIAN ORIGINAL BIOLOGICAL AGENTS FOR THE TREATMENT OF IMMUNOINFLAMMATORY RHEUMATIC DISEASES
The paper analyzes the key biological effects of cytokines that play a central role in the pathogenesis of immunoinflammatory rheumatic diseases. Special attention is drawn to major proinflammatory cytokines, such as tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6), and IL-17. There are data fr...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
IMA PRESS LLC
2017-04-01
|
| Series: | Научно-практическая ревматология |
| Subjects: | |
| Online Access: | https://rsp.mediar-press.net/rsp/article/view/2364 |
| _version_ | 1797862716549890048 |
|---|---|
| author | E. L. Nasonov V. I. Mazurov Yu. V. Usacheva E. V. Chernyaeva Ya. Yu. Ustyugov A. B. Ulitin R. A. Ivanov |
| author_facet | E. L. Nasonov V. I. Mazurov Yu. V. Usacheva E. V. Chernyaeva Ya. Yu. Ustyugov A. B. Ulitin R. A. Ivanov |
| author_sort | E. L. Nasonov |
| collection | DOAJ |
| description | The paper analyzes the key biological effects of cytokines that play a central role in the pathogenesis of immunoinflammatory rheumatic diseases. Special attention is drawn to major proinflammatory cytokines, such as tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6), and IL-17. There are data from a preclinical study of the innovative original biological agents (BAs) designed by the JSC «BIOCAD»: BCD-085, a humanized anti-IL-17 monoclonal antibody, BCD-089, a humanized anti-IL-6 receptor monoclonal antibody, and BCD-121, a humanized bispecific antiTNF-α and anti-IL-17 monoclonal antibody. The preclinical findings prove the specific activity of the drugs in suppressing the inflammatory process, as well as the low toxicity and good tolerance in animals, which could justify investigation of the the drugs during human clinical trials and open up prospects for effective and affordable treatment in Russian patients. |
| first_indexed | 2024-04-09T22:23:59Z |
| format | Article |
| id | doaj.art-59fe075e604e49ccb1590bbacd046b58 |
| institution | Directory Open Access Journal |
| issn | 1995-4484 1995-4492 |
| language | Russian |
| last_indexed | 2024-04-09T22:23:59Z |
| publishDate | 2017-04-01 |
| publisher | IMA PRESS LLC |
| record_format | Article |
| series | Научно-практическая ревматология |
| spelling | doaj.art-59fe075e604e49ccb1590bbacd046b582023-03-22T13:45:52ZrusIMA PRESS LLCНаучно-практическая ревматология1995-44841995-44922017-04-0155220121010.14412/1995-4484-2017-201-2102221DEVELOPMENTS OF RUSSIAN ORIGINAL BIOLOGICAL AGENTS FOR THE TREATMENT OF IMMUNOINFLAMMATORY RHEUMATIC DISEASESE. L. Nasonov0V. I. Mazurov1Yu. V. Usacheva2E. V. Chernyaeva3Ya. Yu. Ustyugov4A. B. Ulitin5R. A. Ivanov6V.A. Nasonova Research Institute of Rheumatology, Moscow Department of Rheumatology, Institute of Professional Education, I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia, MoscowI.I. Mechnikov NorthWestern State Medical University, Ministry of Health of Russia, Saint PetersburgJSC «BIOCAD», Saint PetersburgJSC «BIOCAD», Saint PetersburgJSC «BIOCAD», Saint PetersburgJSC «BIOCAD», Saint PetersburgJSC «BIOCAD», Saint PetersburgThe paper analyzes the key biological effects of cytokines that play a central role in the pathogenesis of immunoinflammatory rheumatic diseases. Special attention is drawn to major proinflammatory cytokines, such as tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6), and IL-17. There are data from a preclinical study of the innovative original biological agents (BAs) designed by the JSC «BIOCAD»: BCD-085, a humanized anti-IL-17 monoclonal antibody, BCD-089, a humanized anti-IL-6 receptor monoclonal antibody, and BCD-121, a humanized bispecific antiTNF-α and anti-IL-17 monoclonal antibody. The preclinical findings prove the specific activity of the drugs in suppressing the inflammatory process, as well as the low toxicity and good tolerance in animals, which could justify investigation of the the drugs during human clinical trials and open up prospects for effective and affordable treatment in Russian patients.https://rsp.mediar-press.net/rsp/article/view/2364anti-il-17 monoclonal antibodiesanti-il-6 receptor monoclonal antibodiesbispecific anti-tnf-α and anti-il-17 monoclonal antibodies |
| spellingShingle | E. L. Nasonov V. I. Mazurov Yu. V. Usacheva E. V. Chernyaeva Ya. Yu. Ustyugov A. B. Ulitin R. A. Ivanov DEVELOPMENTS OF RUSSIAN ORIGINAL BIOLOGICAL AGENTS FOR THE TREATMENT OF IMMUNOINFLAMMATORY RHEUMATIC DISEASES Научно-практическая ревматология anti-il-17 monoclonal antibodies anti-il-6 receptor monoclonal antibodies bispecific anti-tnf-α and anti-il-17 monoclonal antibodies |
| title | DEVELOPMENTS OF RUSSIAN ORIGINAL BIOLOGICAL AGENTS FOR THE TREATMENT OF IMMUNOINFLAMMATORY RHEUMATIC DISEASES |
| title_full | DEVELOPMENTS OF RUSSIAN ORIGINAL BIOLOGICAL AGENTS FOR THE TREATMENT OF IMMUNOINFLAMMATORY RHEUMATIC DISEASES |
| title_fullStr | DEVELOPMENTS OF RUSSIAN ORIGINAL BIOLOGICAL AGENTS FOR THE TREATMENT OF IMMUNOINFLAMMATORY RHEUMATIC DISEASES |
| title_full_unstemmed | DEVELOPMENTS OF RUSSIAN ORIGINAL BIOLOGICAL AGENTS FOR THE TREATMENT OF IMMUNOINFLAMMATORY RHEUMATIC DISEASES |
| title_short | DEVELOPMENTS OF RUSSIAN ORIGINAL BIOLOGICAL AGENTS FOR THE TREATMENT OF IMMUNOINFLAMMATORY RHEUMATIC DISEASES |
| title_sort | developments of russian original biological agents for the treatment of immunoinflammatory rheumatic diseases |
| topic | anti-il-17 monoclonal antibodies anti-il-6 receptor monoclonal antibodies bispecific anti-tnf-α and anti-il-17 monoclonal antibodies |
| url | https://rsp.mediar-press.net/rsp/article/view/2364 |
| work_keys_str_mv | AT elnasonov developmentsofrussianoriginalbiologicalagentsforthetreatmentofimmunoinflammatoryrheumaticdiseases AT vimazurov developmentsofrussianoriginalbiologicalagentsforthetreatmentofimmunoinflammatoryrheumaticdiseases AT yuvusacheva developmentsofrussianoriginalbiologicalagentsforthetreatmentofimmunoinflammatoryrheumaticdiseases AT evchernyaeva developmentsofrussianoriginalbiologicalagentsforthetreatmentofimmunoinflammatoryrheumaticdiseases AT yayuustyugov developmentsofrussianoriginalbiologicalagentsforthetreatmentofimmunoinflammatoryrheumaticdiseases AT abulitin developmentsofrussianoriginalbiologicalagentsforthetreatmentofimmunoinflammatoryrheumaticdiseases AT raivanov developmentsofrussianoriginalbiologicalagentsforthetreatmentofimmunoinflammatoryrheumaticdiseases |